Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
ENGN Stock Chart & Stats
$7.33
$0.17(2.19%)
At close: 4:00 PM EST
$7.33
$0.17(2.19%)
Day’s Range― - ―
52-Week Range$2.65 - $9.65
Previous CloseN/A
Volume16.79K
Average Volume (3M)363.86K
Market Cap
$375.24M
Enterprise Value$23.05M
Total Cash (Recent Filing)$201.91M
Total Debt (Recent Filing)$8.26M
Price to Earnings (P/E)―
Beta-1.77
Next Earnings
Mar 16, 2026EPS EstimateN/A
Last Dividend Ex-Date
Feb 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding51,191,772
10 Day Avg. Volume273,287
30 Day Avg. Volume363,861
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.45
Price to Sales (P/S)0.00
P/FCF Ratio-8.03
Enterprise Value/Market Cap0.06
Enterprise Value/Revenue48.03
Enterprise Value/Gross Profit-235.23
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$23.33Price Target Upside218.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Integration And UsabilityDetalimogene’s value lies in its ease of use, logistical simplicity, and seamless integration into existing outpatient workflows.
Market Share GrowthDetalimogene is positioned to capture sizable market share, particularly within the community practice setting.
Regulatory AdvantageThe FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation allows heightened regulatory interaction and has historically compressed timelines, increasing detalimogene’s chances of capturing share.
Bears Say
enGene Holdings News
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $2.65 and its highest was $9.65 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $375.24M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Mar 16, 2026 which is in 136 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Sep 11, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.498 by -$0.072.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on enGene Holdings dividends here
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 51,191,772 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.498. Following the earnings report the stock price went down -5.776%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
enGene Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.33 (218.28% Upside)
$23.33 (218.28% Upside)
Blogger Sentiment
Bearish
ENGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.55%
12-Months-Change
Fundamentals
Return on Equity
-43.95%
Trailing 12-Months
Asset Growth
-7.99%
Trailing 12-Months
Company Description
enGene Holdings
enGene Holdings (ENGN) is a biotechnology company specializing in the development of innovative gene therapies. The company's core focus is on creating advanced therapeutics for the treatment of chronic diseases by utilizing its proprietary non-viral gene delivery platform. enGene Holdings aims to address unmet medical needs in sectors such as immunology and oncology by offering transformative solutions that enhance patient outcomes.
ENGN Stock 12 Month Forecast
Average Price Target
$23.33
▲(218.28% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Replimune Group
―
Immuneering
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
19.13% Insiders
0.23% Mutual Funds
0.02% Other Institutional Investors
80.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---